Skip to main content
Erschienen in: Cancer Causes & Control 5/2013

01.05.2013 | Original paper

Quantitative exposure metrics for sleep disturbance and their association with breast cancer risk

verfasst von: Jennifer Girschik, Lin Fritschi, Thomas C. Erren, Jane Heyworth

Erschienen in: Cancer Causes & Control | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

It has been acknowledged by those in the field of sleep epidemiology that the current measures of sleep used in many epidemiological studies do not adequately capture the complexity and variability of sleep. A number of ways to improve the measurement of sleep have been proposed. This study aimed to assess the relationship between novel ‘sleep disturbance’ metrics, as expanded measures of sleep, and breast cancer risk.

Methods

Data for this study were derived from a population-based case–control study conducted in Western Australia between 2009 and 2011. Participants completed a self-administered questionnaire that included questions about demographic, reproductive, and lifestyle factors in addition to questions on sleep. Four metrics of exposure to sleep disturbance (cumulative, average, duration, and peak) were developed. Unconditional logistic regression was used to examine the association between metrics of sleep disturbance and breast cancer risk.

Results

There was no evidence to support an association between any of the sleep disturbance metrics and breast cancer risk. Compared with the reference group of unexposed women, the fully adjusted ORs for cumulative sleep disturbance (harm) metric were as follows: 1st tertile 0.90 (95 % CI: 0.72–1.13); OR for the 2nd tertile 1.04 (95 % CI: 0.84–1.29); and OR for the 3rd tertile 1.02 (95 % CI: 0.82–1.27).

Conclusions

This study found no association between several metrics of sleep disturbance and risk of breast cancer. Our experience with developing metrics of sleep disturbance may be of use to others in sleep epidemiology wishing to expand their scope of sleep measurement.
Literatur
1.
Zurück zum Zitat Ferrie J, Kumari M, Salo P, Singh-Manoux A, Kivimaki M (2011) Sleep epidemiology—a rapidly growing field. Int J Epidemiol 40:1431–1437PubMedCrossRef Ferrie J, Kumari M, Salo P, Singh-Manoux A, Kivimaki M (2011) Sleep epidemiology—a rapidly growing field. Int J Epidemiol 40:1431–1437PubMedCrossRef
2.
Zurück zum Zitat Kryger M, Roth T, Dement WC (eds) (2005) Principles and practice of sleep medicine. Elsevier Saunders, Philadelphia Kryger M, Roth T, Dement WC (eds) (2005) Principles and practice of sleep medicine. Elsevier Saunders, Philadelphia
3.
Zurück zum Zitat Liang J-A, Sun L-M, Muo C-H, Sung F-C, Chang S-N, Kao C-H (2012) Non-apnea sleep disorders will increase subsequent liver cancer risk: a nationwide population-based cohort study. Sleep Med 13:869–874PubMedCrossRef Liang J-A, Sun L-M, Muo C-H, Sung F-C, Chang S-N, Kao C-H (2012) Non-apnea sleep disorders will increase subsequent liver cancer risk: a nationwide population-based cohort study. Sleep Med 13:869–874PubMedCrossRef
4.
Zurück zum Zitat Wang X, Cairns BJ, Travis RC (2010) Sleep duration and breast cancer risk: a meta-analysis. J Epidemiol Community Health 64:A32CrossRef Wang X, Cairns BJ, Travis RC (2010) Sleep duration and breast cancer risk: a meta-analysis. J Epidemiol Community Health 64:A32CrossRef
5.
Zurück zum Zitat Wu AH, Wang R, Koh W-P, Stanczyk FZ, Lee H-P, Yu MC (2008) Sleep duration, melatonin and breast cancer among Chinese women in Singapore. Carcinogenesis 29:1244–1248PubMedCrossRef Wu AH, Wang R, Koh W-P, Stanczyk FZ, Lee H-P, Yu MC (2008) Sleep duration, melatonin and breast cancer among Chinese women in Singapore. Carcinogenesis 29:1244–1248PubMedCrossRef
6.
Zurück zum Zitat Pinheiro SP, Schernhammer ES, Tworoger SS, Michels KB (2006) A prospective study on habitual duration of sleep and incidence of breast cancer in a large cohort of women. Cancer Res 66:5521–5525PubMedCrossRef Pinheiro SP, Schernhammer ES, Tworoger SS, Michels KB (2006) A prospective study on habitual duration of sleep and incidence of breast cancer in a large cohort of women. Cancer Res 66:5521–5525PubMedCrossRef
7.
Zurück zum Zitat McElroy J, Newcomb P, Titus-Ernstoff L, Trentham-Dietz A, Hampton J, Egan K (2006) Duration of sleep and breast cancer risk in a large population-based case-control study. J Sleep Res 15:241–249PubMedCrossRef McElroy J, Newcomb P, Titus-Ernstoff L, Trentham-Dietz A, Hampton J, Egan K (2006) Duration of sleep and breast cancer risk in a large population-based case-control study. J Sleep Res 15:241–249PubMedCrossRef
8.
Zurück zum Zitat Verkasalo PK, Lillberg K, Stevens RG, Hublin C, Partinen M, Koskenvuo M, Kaprio J (2005) Sleep duration and breast cancer: a prospective cohort study. Cancer Res 65:9595–9600PubMedCrossRef Verkasalo PK, Lillberg K, Stevens RG, Hublin C, Partinen M, Koskenvuo M, Kaprio J (2005) Sleep duration and breast cancer: a prospective cohort study. Cancer Res 65:9595–9600PubMedCrossRef
9.
Zurück zum Zitat Kakizaki M, Kuriyama S, Sone T, Ohmori-Matsuda K, Hozawa A, Nakaya N, Fukudo S et al (2008) Sleep duration and the risk of breast cancer: the Ohsaki Cohort Study. Br J Cancer 99:1502–1505PubMedCrossRef Kakizaki M, Kuriyama S, Sone T, Ohmori-Matsuda K, Hozawa A, Nakaya N, Fukudo S et al (2008) Sleep duration and the risk of breast cancer: the Ohsaki Cohort Study. Br J Cancer 99:1502–1505PubMedCrossRef
10.
Zurück zum Zitat Wu AH, Stanczyk FZ, Wang R, Koh W-P, Yuan J-M, Yu MC (2013) Sleep duration, spot urinary 6-sulfatoxymelatonin levels and risk of breast cancer among Chinese women in Singapore. Int J Cancer 132:891–896PubMedCrossRef Wu AH, Stanczyk FZ, Wang R, Koh W-P, Yuan J-M, Yu MC (2013) Sleep duration, spot urinary 6-sulfatoxymelatonin levels and risk of breast cancer among Chinese women in Singapore. Int J Cancer 132:891–896PubMedCrossRef
11.
Zurück zum Zitat Girschik J, Heyworth J, Fritschi L (2013) Self-reported sleep duration, sleep quality, and breast cancer risk in a population-based case-control study. Am J Epidemiol [epub ahead of print] doi:10.1093/aje/kws422 Girschik J, Heyworth J, Fritschi L (2013) Self-reported sleep duration, sleep quality, and breast cancer risk in a population-based case-control study. Am J Epidemiol [epub ahead of print] doi:10.​1093/​aje/​kws422
12.
Zurück zum Zitat Erren T (2012) Sleep duration and cancer risk: time to use a “sleep-years” index? Cancer Causes Control 23:1399–1403PubMedCrossRef Erren T (2012) Sleep duration and cancer risk: time to use a “sleep-years” index? Cancer Causes Control 23:1399–1403PubMedCrossRef
13.
Zurück zum Zitat Dijk D-J (2012) Sleep and health: beyond sleep duration and sleepiness? J Sleep Res 21:355–356PubMedCrossRef Dijk D-J (2012) Sleep and health: beyond sleep duration and sleepiness? J Sleep Res 21:355–356PubMedCrossRef
14.
Zurück zum Zitat Erren T (2002) Does light cause internal cancers? The problem and challenge of an ubiquitous exposure. Neuroendocrinol Lett 23(suppl 2):55–64 Erren T (2002) Does light cause internal cancers? The problem and challenge of an ubiquitous exposure. Neuroendocrinol Lett 23(suppl 2):55–64
15.
Zurück zum Zitat Taillard J, Philip P, Bioulac B (1999) Morningness/eveningness and the need for sleep. J Sleep Res 8:291–295PubMedCrossRef Taillard J, Philip P, Bioulac B (1999) Morningness/eveningness and the need for sleep. J Sleep Res 8:291–295PubMedCrossRef
16.
Zurück zum Zitat Girschik J, Heyworth J, Fritschi L (2012) Reliability of a sleep quality questionnaire for use in epidemiological studies. J Epidemiol 22:244–250PubMedCrossRef Girschik J, Heyworth J, Fritschi L (2012) Reliability of a sleep quality questionnaire for use in epidemiological studies. J Epidemiol 22:244–250PubMedCrossRef
17.
Zurück zum Zitat Checkoway H, Pearce N, Kriebel D (2004) Research methods in occupational epidemiology. Oxford University Press, OxfordCrossRef Checkoway H, Pearce N, Kriebel D (2004) Research methods in occupational epidemiology. Oxford University Press, OxfordCrossRef
18.
Zurück zum Zitat Cordier S, Stewart PA (2005) Exposure assessment. In: Ahrens W, Pigeot I (eds) Handbook of epidemiology. Springer, Berlin, pp 437–462CrossRef Cordier S, Stewart PA (2005) Exposure assessment. In: Ahrens W, Pigeot I (eds) Handbook of epidemiology. Springer, Berlin, pp 437–462CrossRef
19.
Zurück zum Zitat Knutson KL, Spiegel K, Penev P, Van Cauter E (2007) The metabolic consequences of sleep deprivation. Sleep Med Rev 11:163–178PubMedCrossRef Knutson KL, Spiegel K, Penev P, Van Cauter E (2007) The metabolic consequences of sleep deprivation. Sleep Med Rev 11:163–178PubMedCrossRef
20.
21.
Zurück zum Zitat Di Milia L, Smith PA, Folkard S (2005) A validation of the revised circadian type inventory in a working sample. Pers Individ Dif 39:1293–1305CrossRef Di Milia L, Smith PA, Folkard S (2005) A validation of the revised circadian type inventory in a working sample. Pers Individ Dif 39:1293–1305CrossRef
22.
Zurück zum Zitat Di Milia L, Smith PA, Folkard S (2004) Refining the psychometric properties of the circadian type inventory. Pers Individ Dif 36:1953–1964CrossRef Di Milia L, Smith PA, Folkard S (2004) Refining the psychometric properties of the circadian type inventory. Pers Individ Dif 36:1953–1964CrossRef
23.
Zurück zum Zitat Australian Government Department of Health and Ageing (2001) Measuring remoteness: accessibility/remoteness index of Australia Australian Government, Department of Health and Ageing, Canberra Australian Government Department of Health and Ageing (2001) Measuring remoteness: accessibility/remoteness index of Australia Australian Government, Department of Health and Ageing, Canberra
24.
Zurück zum Zitat Australian Bureau of Statistics (2006) Census of population and housing: socio-economic indexes for areas (advantage-disadvantage). Australian Bureau of Statistics, Canberra, Australia Australian Bureau of Statistics (2006) Census of population and housing: socio-economic indexes for areas (advantage-disadvantage). Australian Bureau of Statistics, Canberra, Australia
25.
Zurück zum Zitat Ohayon MM (2002) Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 6:97–111PubMedCrossRef Ohayon MM (2002) Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 6:97–111PubMedCrossRef
26.
Zurück zum Zitat Armstrong B, White E, Saracci R (1992) Principles of exposure measurement in epidemiology. Oxford University Press, Oxford Armstrong B, White E, Saracci R (1992) Principles of exposure measurement in epidemiology. Oxford University Press, Oxford
27.
Zurück zum Zitat Colditz G, Baer I, Tamimi R (2006) Chapter 51: breast cancer. In: Schottenfeld D, Fraumeni J (eds) Cancer epidemiology and prevention. Oxford University Press, New York, NY, pp 995–1012CrossRef Colditz G, Baer I, Tamimi R (2006) Chapter 51: breast cancer. In: Schottenfeld D, Fraumeni J (eds) Cancer epidemiology and prevention. Oxford University Press, New York, NY, pp 995–1012CrossRef
Metadaten
Titel
Quantitative exposure metrics for sleep disturbance and their association with breast cancer risk
verfasst von
Jennifer Girschik
Lin Fritschi
Thomas C. Erren
Jane Heyworth
Publikationsdatum
01.05.2013
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 5/2013
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-013-0168-2

Weitere Artikel der Ausgabe 5/2013

Cancer Causes & Control 5/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.